

Certificate of Analysis

MEK2, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-528, 14-528-K, 14-528M

Parent Lot # WAD0049

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged recombinant, full-length human MEK2 expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA agarose, activated using c-Raf (cat# 14-352) and then re-purified using Ni²⁺/NTA agarose. Purity 95% by SDS-PAGE and Coomassie blue staining. MW = 46kDa.

Specific Activity (Parent lot# WAD0049): 3954U/mg, where one unit of MEK2, active activity is defined as the amount of MEK2 which activates 1µM MAPK2 (cat# 14-198) by 1 unit per minute at 30°C using 100µM ATP. One unit of MAPK2 activity is defined as 1nmol phosphate incorporated into 0.33mg/ml myelin basic protein (MBP) per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 0.40mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 0.31–5ng of this lot of enzyme phosphorylated 1µM inactive MAPK2 in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as MEK2 with the translated sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x MAPK2 Activation buffer:** 250mM Tris/HCl pH7.5, 1mM EGTA, 1% 2-mercaptoethanol, 0.05% Brij-35.
2. **10 x Reaction Buffer:** 250mM Tris/HCl pH7.5, 0.2mM EGTA.
3. **MAPK2 inactive:** Use at a final assay concentration of 1 μ M (0.067mg/ml). Prepare a 0.67mg/ml stock and add 2.5 μ l of stock per assay point. Prepare using MEK2 dilution buffer.
4. **Myelin Basic Protein (MBP):** Use at a final assay concentration of 0.33mg/ml. Prepare a 3.33mg/ml stock and add 2.5 μ l of stock per assay point.
5. **MEK2, active:** Dilute with 50mM Tris/HCl pH7.5, 0.1mM EGTA, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 0.31–5ng per assay point.
6. **Stage One 5 x Mg/ATP:** 50mM magnesium acetate, 0.5mM ATP.
7. **[γ -³³P]ATP:** 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure:

Stage One: *Activation of MAPK2.*

1. Add 5 μ l of MAPK2 activation buffer to a microcentrifuge tube.
2. Add 2.5 μ l of **MAPK2 inactive**.
3. Add **2.5 μ l (0.31–5ng) MEK2, active**.
4. Add 10 μ l of dH₂O.
5. Add 5 μ l of stage one Mg/ATP mixture.
6. Incubate for 15 minutes at 30°C.
7. Immediately transfer 1 μ l of the mixture to the **Stage Two** component mixture.

Stage Two: *Phosphorylation of MBP by activated MAP kinase 2 (96 well plate format):*

1. Add 2.5 μ l of 10 x reaction buffer per assay to wells.
2. Add 2.5 μ l of **MBP**.
3. Add 9 μ l of dH₂O.
4. Add 10 μ l of diluted [γ -³³P] ATP mixture.
5. Add 1 μ l of **Stage One** reaction product.
6. Incubate for 15 minutes at 30°C.
7. Stop the reaction by adding 5 μ l 3% phosphoric acid.
8. Transfer a 10 μ l aliquot onto the appropriate area of a **P30 Filtermat**.
8. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
9. Wash the filtermat once for 2 minutes with methanol.
10. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
11. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 μ l of 30% phosphoric acid.

Certificate of Analysis

MEK2 Sequence Information

Protein	Human MEK2
Tags	N-terminal 6His
Native sequence	M10 of the recombinant protein is equivalent to M1 of human MEK2
Accession number	GenBank NM_030662

Recombinant MEK2 amino acid sequence:

```

1  MHHHHHHEFM LARRKPVLP LTIINPTAEG PSPTSEGASE ANLVDLQKKL EELELDEQQK
61  KRLEAFLTQK AKVGELKDDD FERISELGAG NGGVVTKVQH RPSGLIMARK LIHLEIKPAI
121 RNQIIRELQV LHECNTPYIV GFYGAFYSDG EISICMEHMD GGLDQVLKE AKRIPEEILG
181 KVSIAVLRGL AYLREKHQIM HRDVKPSNIL VNSRGEIKLC DFGVSGQLID SMANSFVGTR
241 SYMAPERLQG THYSVQSDIW SMGLSLVELA VGRYPIPPPD AKELEAIFGR PVVDGEEGEP
301 HSISPRPRPP GRPVS GHGMD SRPAMAFEL LDYIVNEPPP KLPNGVFTPD FQEFVNKCLI
361 KNPAERADLK MLTNHTFIKR SEVEEVDFAG WLCKTLRLNQ PGTPTRTAV

```

Recombinant MEK2 nucleotide sequence:

```

1  atgcatcatc accatcacca tgaattcatg ctggcccggg ggaagccggt gctgccggcg
61  ctcaccatca accctaccat cgccgagggc ccatccccta ccagcgaggg cgcctccgag
121 gcaaacctgg tggacctgca gaagaagctg gaggagctgg aacttgacga gcagcagaag
181 aagcggctgg aagcctttct caccagaaa gccaaagctg gcgaactcaa agacgatgac
241 ttcgaaagga tctcagagct gggcgcgggc aacggcgggg tggtcaccaa agtccagcac
301 agaccctcgg gcctcatcat ggccaggaag ctgatccacc ttgagatcaa gccggccatc
361 cggaaaccaga tcatccgcga gctgcaggtc ctgcacgaat gcaactcgcc gtacatcgtg
421 ggcttctacg gggccttcta cagtacggg gagatcagca tttgcatgga acacatggac
481 ggcggtctcc tggaccaggt gctgaaagag gccaaagagga ttcccgagga gatcctgggg
541 aaagtcagca tcgcggttct ccggggcttg gcgtacctcc gagagaagca ccagatcatg
601 caccgagatg tgaagccctc caacatcctc gtgaactcta gaggggagat caagctgtgt
661 gacttcgggg tgagcgggca gctcatagac tccatggcca actccttcgt gggcacgcgc
721 tcctacatgg ctccggagcg gttgcagggc acacattact cgggtgcagtc ggacatctgg
781 agcatggggc tgtccctggt ggagctggcc gtcggaaggt acccatccc ccgcccgcac
841 gccaaagagc tggaggccat ctttggccgg ccggtggtcg acggggaaga aggagagcct
901 cacagcatct cgctcggcc gagggccccg gggcgccccg tcagcgggtc cgggatggat
961 agccggcctg ccatggccat ctttgaactc ctggactata ttgtgaacga gccacctcct
1021 aagctgcccc acggtgtgtt caccgccgac ttccaggagt ttgtcaataa atgcctcatc
1081 aagaacccag cggagcgggc ggacctgaag atgctcacia accacacctt catcaagcgg
1141 tccgaggtgg aagaagtggg ttttgcgggc tggttgtgta aaacctgctg gctgaaccag
1201 cccggcacac ccacgcgcac cgccgtgtga

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.